Latest news
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila TimesThe Manila Times · Fri, 07 Aug 2026 20:26:03 GMTAvalo Therapeutics Announces Plans for Phase 3 Abdakibart HS Program, Advancement of AVTX-010 and Second Quarter 2026 Financial Results - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:15:00 GMTAN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - natlawreview.comnatlawreview.com · Mon, 03 Aug 2026 18:05:23 GMTCullinan Therapeutics Announces Positive FDA Feedback for CLN-049 and Plans Potentially Registrational Phase 2 Study in Relapsed/Refractory AML - MoomooMoomoo · Tue, 28 Jul 2026 11:13:00 GMTFor AML patients with limited options, Cullinan plans a new study - Stock TitanStock Titan · Tue, 28 Jul 2026 07:00:00 GMT